Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics
American Journal of Hematology · 2026-07 · 101 (7) · 1632-1649
DOI: 10.1002/ajh.70304 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 17.04.2026. Verfasst von Fangfang Yan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Drug Resistance, Neoplasm, Pyrimidines, Protein Kinase Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Steve and Nancy Fox Research Funds, NCI NIH HHS, CPRIT SINGLE CORE Facilities Grant.
Abstract (Originalsprache)
Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on longitudinal MCL patient samples. Our analyses revealed both genetic and non‐genetic routes of resistance: In some patients, resistance involves sequential copy number gains (e.g., 1q, 2p, and 8q) accompanied by transcriptomic reprogramming and epigenetic alterations, whereas in others, resistance occurs through non‐genetic mechanisms driven by transcriptional and epigenetic remodeling. Integration of scATAC‐seq and scRNA‐seq enabled gene regulatory network inference and in silico perturbation analysis, highlighting RAD21 and SMC3, core components of the cohesin complex, as chromatin regulators whose downregulation may re‐sensitize cells to PBN. A stem‐like malignant B cell population enriched in resistant samples exhibited features of metabolic reprogramming and epithelial‐mesenchymal transition. Together, our findings highlight heterogeneous, multi‐layered mechanisms of PBN resistance and suggest chromatin regulators as potential therapeutic targets to overcome PBN resistance in MCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Therapeutic Innovation Center, Baylor College of Medicine, Houston, Texas, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Sairah Ahmed, Michael Wang
Förderung
- Steve and Nancy Fox Research Funds
- NCI NIH HHS
- CPRIT SINGLE CORE Facilities Grant
- NIH Shared Instrument Grant
Zitieren
APA
Yan, F., Liu, Y., Lee, H. H., Wang, W., McIntosh, J., Li, Y., Vargas, J., Fei, Y., Ahmed, S., Simon, L. M., & Wang, M. (2026). Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics. American Journal of Hematology, 101(7), 1632-1649. https://doi.org/10.1002/ajh.70304
Vancouver
Yan F, Liu Y, Lee HH, Wang W, McIntosh J, Li Y, et al. Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics. American Journal of Hematology. 2026;101(7):1632-1649. doi:10.1002/ajh.70304
BibTeX
@article{Yan2026,
author = {Yan, Fangfang and Liu, Yang and Lee, Heng-Huan and Wang, Wei and McIntosh, Joseph and Li, Yijing and Vargas, Jovanny and Fei, Yue and Ahmed, Sairah and Simon, Lukas M and Wang, Michael},
title = {Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {7},
pages = {1632--1649},
doi = {10.1002/ajh.70304}
}
EUVIMED